Louisiana State Employees Retirement System Makes New $382,000 Investment in Xencor, Inc. $XNCR

Louisiana State Employees Retirement System bought a new stake in Xencor, Inc. (NASDAQ:XNCR) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 31,700 shares of the biopharmaceutical company’s stock, valued at approximately $382,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Wealth Enhancement Advisory Services LLC bought a new position in shares of Xencor during the fourth quarter worth about $81,000. Tower Research Capital LLC TRC raised its holdings in shares of Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 3,018 shares during the last quarter. E Fund Management Co. Ltd. acquired a new position in shares of Xencor during the second quarter worth approximately $79,000. NorthCrest Asset Manangement LLC bought a new position in Xencor in the 4th quarter worth approximately $149,000. Finally, Norges Bank acquired a new stake in Xencor in the 4th quarter valued at approximately $175,000.

Xencor Stock Performance

Shares of NASDAQ XNCR opened at $16.46 on Thursday. The stock has a fifty day moving average price of $12.76 and a two-hundred day moving average price of $12.77. The firm has a market cap of $1.22 billion, a P/E ratio of -7.19 and a beta of 0.86. Xencor, Inc. has a 1 year low of $6.92 and a 1 year high of $18.69.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.96). The firm had revenue of $4.52 million during the quarter, compared to the consensus estimate of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The firm’s quarterly revenue was down 86.2% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.66) EPS. On average, research analysts predict that Xencor, Inc. will post -3.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on XNCR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Wednesday, June 24th. JPMorgan Chase & Co. raised their price target on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Monday, May 11th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research note on Monday. Truist Financial reduced their price objective on shares of Xencor from $29.00 to $27.00 and set a “buy” rating for the company in a report on Tuesday. Finally, Wall Street Zen lowered shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 9th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.